Page 8 - Human Use News Today

AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering. The Cambridge,...

Londons FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week. Focus this week will be on...

Roche announces that the European Medicines Agencys Committee for Medicinal Products for Human Use has recommended approval of subcutaneous Ocrevus for its indications in multiple sclerosis .A...

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or ...

The EMA’s CHMP recommended capivasertib/fulvestrant for ER-positive, HER2-negative advanced breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Takeda TSE4502NYSETAK today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval of fruquintinib a selective inhibitor of vascular endothelial growth factor receptors VEGFR 1 2 and 3 for the treatment of adult patients with previously treated metastatic colorectal cancer mCRC.

By Colin Kellaher Bristol Myers Squibb on Friday said the European Medicines Agencys Committee for Medicinal Products for Human Use recommended expanded approval of its blockbuster cancer...

Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ as the first and only endothelin receptor...

Roche announced today that the European Medicines Agencys Committee for Medicinal Products for Human Use has recommended approval of Alecensa as monotherapy, as adjuvant therapy in patients with...

(MENAFN - GlobeNewsWire - Nasdaq) Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGOTM ... ...